Cover Image

The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib

Background - Impact of patient and tumour baseline characteristics on the overall survival is not well characterized in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. - Aims/methods - Univariate/multivariate analyses were conducted to identify retrospectively the impac...

Full description

Saved in:
Bibliographic Details
Main Authors: Wörns, Marcus A. (Author) , Koch, Sandra (Author) , Niederle, Ina M. (Author) , Marquardt, Jens U. (Author) , Nguyen-Tat, Marc (Author) , Gamstätter, Thomas (Author) , Schuchmann, Marcus (Author) , Schulze-Bergkamen, Henning (Author) , Galle, Peter R. (Author) , Weinmann, Arndt (Author)
Format: Article (Journal)
Language:English
Published: 2013
In: Digestive and liver disease
Year: 2013, Volume: 45, Issue: 5, Pages: 408-413
ISSN:1878-3562
DOI:10.1016/j.dld.2012.10.010
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.dld.2012.10.010
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S1590865812004082
Get full text
Author Notes:Marcus A. Wörns, Sandra Koch, Ina M. Niederle, Jens U. Marquardt, Marc Nguyen-Tat, Thomas Gamstätter, Marcus Schuchmann, Henning Schulze-Bergkamen, Peter R. Galle, Arndt Weinmann
Description
Summary:Background - Impact of patient and tumour baseline characteristics on the overall survival is not well characterized in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. - Aims/methods - Univariate/multivariate analyses were conducted to identify retrospectively the impact of baseline characteristics on the survival of 110 patients with advanced HCC treated with sorafenib. - Results - Median survival of the whole cohort was 6.7 months, median survival in Child-Pugh A, B, C patients was 10.5, 6.1 and 3.0 months and median survival of patients with Barcelona Clinic Liver Cancer (BCLC) stage C/D was 6.8/2.6 months. Presence of ascites, presence of macrovascular invasion and BCLC stage D (mainly determined by Child-Pugh C status and Eastern Cooperative Oncology Group Performance Status>2) remained independent prognostic factors for the survival on multivariate analysis. Particularly, the presence of macrovascular invasion significantly influenced survival both in patients with liver cirrhosis Child-Pugh A and Child-Pugh B. - Conclusion - Well maintained liver function and performance status are prerequisites for sorafenib treatment in patients with advanced HCC. Our findings do not support routine clinical use of sorafenib in Child-Pugh B patients. Evaluation of ascites and particularly macrovascular invasion might help to identify patients more likely to benefit from sorafenib treatment.
Item Description:Available online 21 November 2012
Gesehen am 18.11.2021
Physical Description:Online Resource
ISSN:1878-3562
DOI:10.1016/j.dld.2012.10.010

Similar Items